Neogenis Doubts NAD’s Expertise, Appeals Decision On Claims
This article was originally published in The Tan Sheet
Neogenis appeals to the National Advertising Review Board NAD’s recommendation to discontinue Neo40 Daily claims including “proven to help the body naturally increase its nitric oxide levels.” The firm criticizes NAD attorneys for imposing their “non-expert view” over medical experts’ findings.
You may also be interested in...
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”
Judge ordering permanent injunction against Confidence USA on a complaint filed in 2019 questioned FDA's calculations for requiring the firm to recall and destroy all products it had distributed since February 2018.
White House, Democrat majority in Congress and likely next FTC chair support the agency wielding the authority, says advertising law attorney Holly Melton. Supreme Court, though, likely will rule in pending cases that a strict reading of an FTC regulation doesn’t grant monetary penalty authority.